BAUSCH HEALTH COMPANIES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.95 CAD | +4.19% |
|
+2.87% | -15.71% |
| Sales 2024 * | 9.4B 12.8B 784B | Sales 2025 * | 9.67B 13.16B 806B | Capitalization | 2.41B 3.28B 201B |
|---|---|---|---|---|---|
| Net income 2024 * | 148M 202M 12.34B | Net income 2025 * | 389M 530M 32.45B | EV / Sales 2024 * | 2.43 x |
| Net Debt 2024 * | 20.44B 27.83B 1,705B | Net Debt 2025 * | 19.09B 26B 1,592B | EV / Sales 2025 * | 2.22 x |
| P/E ratio 2024 * |
19.5
x | P/E ratio 2025 * |
6.23
x | Employees | 20,270 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bausch Health Companies Inc.
More recommendations
More press releases
More news
| 1 day | +4.31% | ||
| 1 week | +2.87% | ||
| Current month | +0.11% | ||
| 1 month | -18.91% | ||
| 3 months | -33.13% | ||
| 6 months | -9.77% | ||
| Current year | -15.71% |
1 week
8.32
8.96
1 month
8.3211.03
Current year
8.3215.43
1 year
8.3215.43
3 years
5.1038.96
5 years
5.1043.97
10 years
5.10347.84
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Appio
CEO | Chief Executive Officer | 61 | - |
John Barresi
DFI | Director of Finance/CFO | 51 | 24/22/24 |
| Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Power
BRD | Director/Board Member | 67 | 01/08/01 |
John Paulson
CHM | Chairman | 68 | 01/17/01 |
Steven Miller
BRD | Director/Board Member | 35 | 17/21/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 8.95 | +4.19% | 794,180 |
| 30/24/30 | 8.59 | +2.14% | 273,742 |
| 29/24/29 | 8.41 | -0.59% | 253,077 |
| 28/24/28 | 8.46 | -0.59% | 396,718 |
| 27/24/27 | 8.51 | -2.30% | 141,873 |
Delayed Quote Toronto S.E., May 01, 2024 at 01:30 am IST
More quotes
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Sector
Pharmaceuticals
Calendar
06/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
6.56
USD
Average target price
9.786
USD
Spread / Average Target
+49.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- BHC Stock
- BHC Stock
